DOP Session 1

  • 17:30-18:30 Digital Oral Presentation Session 1 – Current understanding, efficacy and safety of biologics
    Room: Lehar 1-3, Ground Floor, Congress Centre
    Chairs:
    Miguel Regueiro, Pittsburgh, United States
    Britta Siegmund, Berlin, Germany

      17:30-17:36 DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicentre retrospective European Crohn’s and Colitis Organisation study 
    U. Kopylov1, B. Verstockt2, L. Biedermann3, S. Sebastian4, D. Pugliese5, E. Sonnenberg6, P.R. Steinhagen6, N. Arebi7, Y. Ron8, T. Kucharzik9, X. Roblin10, B. Ungar1, A. Bar-Gil Shitrit11, S. Ardizzone12, P. Molander13, M. Coletta14, L. Peyrin-Biroulet15, P. Bossuyt16, I. Avni-Biron17, E.i. Tsoukal18, M. Allocca19, K. Katsanos20, T. Raine21, T. Sipponen22, G. Fiorino23, S. Ben-Horin1, R. Eliakim1, A. Armuzzi5, B. Siegmund6, D.C. Baumgart6, N. Kamperidis7, N. Maharshak8, C. Maaser9, G. Mantzaris18, H. Yanai17, D. Christodoulou20, I. Dotan17, M. Ferrante2 
    1. Sheba Medical Center, Gastroenterology, Ramat Gan, Israel
    2. KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium
    3. University of Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland
    4. Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom
    5. IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, internal Medicine, Gastroenterology Division, Rome, Italy
    6. Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany
    7. LNWH ST MARKS HOSPITAL, Harrow, United Kingdom
    8. Tel Aviv Medical Ceter, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel
    9. Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany
    10. CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France
    11. Shaare Zedek Medical Center, Digestive diseases Institute, Jerusalem, Israel
    12. ASST Fatebenefratelli - Sacco, Milan, Italy
    13. Helsinki University Central Hospital, Department of Gastroenterology, Department of Medicine, Helsinki, Finland
    14. -Department of Pathophysiology and Transplantation, Gastroenterology and Endoscopy Unit,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Università degli Studi di Milano,Milan, Italy, Gatroenterology, Milan, Italy
    15. Nancy University Hospital, Université de Lorraine, Hepatogastroenterology, Vandoeuvre-lès-Nancy, France
    16. Imelda GI clinical research center,, Gastroenterology, Bonheiden, Belgium
    17. Rabin Medical Center, Department of Gastroenterology and Liver Diseases, Petach Tikva, Israel
    18. Evaggelismos Hospital, Gastroenterology, Athens, Greece
    19. Humanitas Gradenigo, Gastroenterology, Turin, Italy
    20. University of Ioannina, Gastroenterology, Ioannina, Greece
    21. Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom
    22. Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland
    23. Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy
      17:36-17:42 DOP002: Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
    S. Vermeire1, E.V. Loftus Jr.2, J.M. Khalid3, D. Tudor4, M. Akbari5, D. Demuth3, L. Peyrin-Biroulet6
    1. University Hospitals Leuven, Department of clinical and experimental medicine, Leuven, Belgium
    2. Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, Minnesota, United States
    3. Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom
    4. Takeda Pharmaceuticals International AG, Zurich, Switzerland
    5. Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, United States
    6. Nancy University Hospital, Lorraine University, Department of Gastroenterology, Nancy, France
      17:42-17:48 DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world belgian cohort study
    C. Liefferinckx1, 2, B. Verstockt3, A. Gils4, M. Noman3, C. Van Kemseke5, E. Macken6, M. De Vos7, W. Van Moerkercke8, J.-F. Rahier9, P. Bossuyt10, J. Dutré11, E. Humblet12, D. Staessen13, H. Peeters14, P. Van Hootegem15, E. Louis5, D. Franchimont1, 2, F. Baert16, S. Vermeire3
    1. Hopital Erasme, ULB, Department of gastroenterology, Brussels, Belgium
    2. Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium
    3. University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
    4. KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
    5. Centre Hospitalier Universitaire Sart-Tilman, ULG, Department of Gastroenterology, Liège, Belgium
    6. Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium
    7. Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium
    8. AZ Groeninge, department of Gastroenterology, Kortrijk, Belgium
    9. Centre Hospitalier Universitaire Mont-Godinne, UCL, Department of Gastroenterology, Yvoir, Belgium
    10. Imeldaziekenhuis, department of Gastroenterology, Bonheiden, Belgium
    11. Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium
    12. Ziekenhuis Oost-Limburg - Campus Sint-Jan, department of Gastroenterology, Genk, Belgium
    13. GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium
    14. Algemeen Ziekenhuis Sint-Lucas, department of Gastroenterology, Gent, Belgium
    15. Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium
    16. AZ Delta, Department of gastroenterology, Roeselare-Menen, Belgium  
      17:48-17:54 DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACY
    P. Bossuyt1, R. Atreya2, C. Taxonera3, 4, X. Hebuterne5, 6, K. Isaacs7, P.D. Higgins8, J. Lindsay9, G. Heap10, D. Arikan10, V. Kuehnl11, J. Petersson10, A.M. Robinson10, E.V. Loftus Jr.12
    1. Imelda General Hospital, Bonheiden, Belgium
    2. Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany
    3.
    Hospital Clínico San Carlos, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Madrid, Spain

    4. Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
    5. Service de Gastroentérologie et Nutrition Clinique, Nice, France
    6. Université de Nice-Sophia-Antipolis, Nice, France
    7. University of North Carolina, Division of Gastroenterology and Hepatology, Chapel Hill, United States
    8. University of Michigan, Ann Arbor, United States
    9. Queen Mary University of London, Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, London, United Kingdom
    10. AbbVie Inc., North Chicago, United States
    11. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
    12. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States
      17:54-18:00 DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists
    R. Cohen1F. Bhayat2, G. Hantsbarger2, A. Blake3, S. Vermeire4

    1. Inflammatory Bowel Disease Center, University of Chicago Medicine, Department of Medicine, Chicago, United States
    2. Takeda Development Center Americas, Inc., Cambridge, United States
    3. Takeda International - UK Branch, London, United Kingdom
    4. University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
       18:00-18:06 DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel Disease
    J. Meserve1, S. Aniwan2, J.L. Koliani-Pace3, P. Shashi4, A. Weiss5, D. Faleck6, A. Winters6, S. Chablaney6, G. Kochhar4, B. Boland1, S. Singh1, R. Hirten6, E. Shmidt6, M. Bohm7, S. V Sagi7, M. Fischer7, D. Lukin5, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen4, B.E. Sands6, J.-F. Colombel6, C.A. Siegel3, W.J. Sandborn1P.S. Dulai1
    1. University of California - San Diego, La Jolla, United States
    2. Mayo Clinic, Rochester, United States
    3. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    4. Cleveland Clinic Foundation, Cleveland, United States
    5. Montefiore Medical Center, New York, United States
    6. Icahn School of Medicine at Mount Sinai, New York, United States
    7. Indiana University, Indianapolis, United States
    8. New York University (NYU), New York, United States
    9. North Shore University Hospital, Manhasset, United States
    10. Lenox Hill Hospital, New York, United States
    11. University of Mississippi, Jackson, United States
       18:06-18:12 DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel Disease
    R. Bor1, F. Klaudia2, P. Miheller3, K. Palatka4, T. Szamosi5, Á. Vincze6, M. Rutka7, K. Szántó2, A. Bálint2, Z. Szepes2, F. Nagy2, Á. Milassin2, A. Fábián2, Á. Csontos3, P. Golovics5, L. Lakner8, K. Müllner3, M. Papp9, Á. Salamon10, K. Sarang8, Z. Vitális4, E. Schafer11, P. Sarlós6, T. Molnár2
    1. University of Szeged, First Department of Medicine, Szaged, Hungary
    2. University of Szeged, First Department of Medicine, Szeged, Hungary
    3. Semmelweis University, 2nd Department of Medicine, Budapest,
    Hungary
    4. University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary
    5. Hungarian Defence Force Military Hospital, Department of Gastroenterology, Budapest, Hungary
    6. University of Pécs, 1st Department of Medicine, Pécs, Hungary
    7. Uversity of Szeged, First Department of Medicine, Szeged, Hungary
    8. Markusovszky Teaching Hospital, Szombathely, Hungary
    9. University of Debrecen, 2nd Department of Medicine, Szeged,
    Hungary
    10. Balassa János Hospital, Szekszárd, Hungary
    11. Semmelweis University, 2nd Department of Medicine, Szeged, Hungary
      18:12-18:18 DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registry
    D. Turner1, S. Koletzko2, H. Winter3, R. Baldassano4, M. Dubinsky5, W. Faubion6, J. Hyams7, S. Kugathasan8, J. Rosh9, J. Escher10, A. Griffiths11, J. Kierkus12, R. Russell13, G. Heap14, D. Arikan14, V. Kuehnl15, J. Petersson14, A. Robinson16F. Ruemmele17
    1. Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel
    2. Dr. von Hauner Children’s Hospital, University Medical Center, LMU Munich, Munich, Germany
    3. Department of Pediatrics, Massachusetts General Hospital, Boston, United States
    4. Pediatric Gastroenterology, The Children’s Hospital of Philadelphia, Philadelphia, United States
    5. Department of Pediatrics, Division of Gastroenterology, Mount Sinai Medical Center, New York, United States
    6. Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States
    7. Division of Digestive Diseases, Connecticut Children’s Medical Center, Hartford, United States
    8. Department of Pediatrics, Emory University School of Medicine & Children’s Healthcare of Atlanta, Atlanta, United States
    9. Division of Gastroenterology and Nutrition, Goryeb Children’s Hospital, Morristown, United States
    10. Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, Netherlands
    11. Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
    12. Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children’s Memorial Health Institute, Warsaw, Poland
    13. Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom
    14. AbbVie Inc., North Chicago, United States
    15. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
    16. Abbvie, Inc., North Chicago, United States
    17. Paediatric Gastroenterology, Hôpital Necker Enfants Malades, APHP,
    University Paris Descartes Sorbonne Paris Cité, Paris, France
      18:18-18:24 DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysis
    D. Lukin1, A. Weiss1, S. Aniwan2, S. Kadire3, G. Tran3, M. Rahal3, D. Faleck4, A. Winters4, S. Chablaney4, J. Meserve5, G. Kochhar6, P. Shashi6, J.L. Koliani-Pace7, M. Bohm3, S. V Sagi3, M. Fischer3, B. Boland5, S. Singh5, R. Hirten4, E. Shmidt4, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen6, B.E. Sands4, W.J. Sandborn5, J.-F. Colombel4, C.A. Siegel7P.S. Dulai5
    1. Montefiore Medical Center, New York, United States
    2. Mayo Clinic, Rochester, United States
    3. Indiana University, Indianapolis, United States
    4. Icahn School of Medicine at Mount Sinai, New York, United States
    5. University of California - San Diego, La Jolla, United States
    6. Cleveland Clinic Foundation, Cleveland, United States
    7. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    8. New York University (NYU), New York, United States
    9. North Shore University Hospital, Manhasset, United States
    10. Lenox Hill Hospital, New York, United States
    11. University of Mississippi, Jackson, United States